What question did this study set out to answer?

To compare the efficacy of azacitidine monotherapy versus combination regimens for post-HSCT maintenance in high-risk myeloid malignancies.

November 11, 2025International Journal of HematologyOpen Access

Azacitidine monotherapy versus combination regimens as post-HSCT maintenance therapy in high-risk myeloid malignancies: a retrospective cohort study

View Full Paper

Ask AI

Bookmark

Authors

YSYing Shen PZPengyu Zhang AHAili He

Discussion

Member takes

Implication

Retrospective cohort study compares relapse rates of azacitidine monotherapy and combination regimens in post-HSCT maintenance therapy, suggesting comparable efficacy.

Key Points

To compare the efficacy of azacitidine monotherapy versus combination regimens for post-HSCT maintenance in high-risk myeloid malignancies.
Retrospective cohort study with 59 patients (AML = 56, MDS = 3)
Patients received AZA-based maintenance post-allo-HSCT as monotherapy or combination regimens
Relapse rates, relapse-free survival, overall survival, and adverse events were evaluated.
Overall relapse rate was 10.2% across groups
3-year relapse-free survival was 89.4% with no significant difference (RFS P = 0.975)
Overall survival was 84.4% with no significant difference (OS P = 0.770)
Adverse event rates showed no significant difference, but febrile reactions were more common with IFN-α.

Cite This Study

Shen et al. (2025) studied this question.

synapsesocial.com/papers/69252e96c0ce034ddc356179 https://doi.org/10.1007/s12185-025-04097-8

View Full Paper

Ask AI

Bookmark

Implication

Retrospective cohort study compares relapse rates of azacitidine monotherapy and combination regimens in post-HSCT maintenance therapy, suggesting comparable efficacy.

Azacitidine monotherapy versus combination regimens as post-HSCT maintenance therapy in high-risk myeloid malignancies: a retrospective cohort study

Discussion

Member takes

Implication

Key Points

Cite This Study

Azacitidine monotherapy versus combination regimens as post-HSCT maintenance therapy in high-risk myeloid malignancies: a retrospective cohort study

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider